Mandate

Vinge advises Industrifonden in coNnection with investment in FishBrain

November 21, 2013

Industrifonden has invested MSEK 5 in FishBrain, a company which has developed a mobile solution and a social network for sport fishermen. Sport fishing is the world’s most popular leisure time activity with 100 million sport fishermen worldwide. The capital will be used to implement the business model and to finance the company’s international expansion.

FishBrain’s mobile solution and social network connects sport fishermen, distributors, manufacturers of sport fishing equipment and arrangers of sport fishing trips. It makes it possible for fishing enthusiasts worldwide to share information, tips and compare fish caught and locations.
The company’s vision is to be the leading global social network for sport fishermen and to continue its expansion in the Nordic region, the UK, Russia, China, the US and Japan.

Vinge’s team consisted of responsible partner Johan Larsson, together with partner Jonas Bergström and associate Karl Hahtovirta.

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024